Navigation Links
CryoLife to Present at 25th Annual Piper Jaffray Healthcare Conference
Date:11/25/2013

ATLANTA, Nov. 25, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at The New York Palace Hotel in New York City.

A live webcast of the Company's presentation is scheduled to begin at 3:00 p.m. ET and will feature a brief overview of the company by D. Ashley Lee, executive vice president, chief operating officer and chief financial officer, followed by a question and answer session.  

The live webcast can be accessed through CryoLife's website, www.cryolife.com, on the Investor Relations page.  An archived copy of the webcast will be available for 90 days on the same website.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

For additional information about the company, visit CryoLife's website:
http://www.cryolife.com.

Contacts:

CryoLife                                                                                   The Ruth Group  
D. Ashley Lee                                                                            Nick Laudico / Zack Kubow
Executive Vice President, Chief Financial Officer                           646-536-7030 / 7020
and Chief Operating Officer                                                          nlaudico@theruthgroup.com
Phone: 770-419-3355
                                                                  zkubow@theruthgroup.com


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... http://www.researchandmarkets.com/research/jsc97m/global ) ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, players ... offering. --> http://www.researchandmarkets.com/research/jsc97m/global ) ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, players ... offering. --> Research and ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest ... is the first of its kind in the ... tattoos through advanced laser treatment. The physician-owned and ... Suncoast by storm with its revitalizing ... and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... Feb. 5, 2016 Dehaier Medical Systems ... the "Company"), which develops, markets and sells medical ... China and international markets, today ... aims to concentrate the Company,s resources to develop ... business and to focus more on its major ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood ... his medical and surgical expertise. Technically known as deoxycholic acid or previously as ... a non-surgical alternative for reduction of fat below the chin (aka the “double ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... disorder treatment helps to reduce the frequency and level of relapse. ... Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the recovery ...
Breaking Medicine News(10 mins):